Maitake D-Fraction & Cancer
68.8% breast cancer response
In Kodama's 165-patient case series, 68.8% of breast cancer patients showed regression or significant symptom improvement with MD-fraction, though this was an uncontrolled case series, not a randomized trial.
Kodama N et al., Alternative Medicine Review, 2002
34
breast cancer survivors tested at Memorial Sloan Kettering in the only human clinical trial (Deng 2009)
BAK-1
the pro-death gene D-fraction turns on in breast cancer cells, triggering apoptosis (Soares 2011)
0.1–5 mg/kg
dose range tested in the MSKCC phase I/II trial, taken twice daily
Kodama N et al., Alternative Medicine Review, 2002
View as image ↗In 2009, a research team at Memorial Sloan Kettering Cancer Center enrolled 34 postmenopausal women who had completed breast cancer treatment and tested maitake D-fraction on their immune function. The extract was given at doses ranging from 0.1 to 5 milligrams per kilogram of body weight, twice daily. The result was one of the most counterintuitive findings in the mushroom research literature: at intermediate doses, the extract suppressed immune function rather than enhancing it.
That finding, from Deng et al.,[1] is the data point anyone researching maitake breast cancer D-fraction most needs to understand. It's also the finding that competitor sites either skip entirely or mention without explaining.
The research on D-fraction and breast cancer spans three distinct tiers: laboratory studies in cell lines, a large non-randomized case series, and the MSKCC clinical trial. Each tier tells a different part of the story. None of them alone is enough to draw firm clinical conclusions. Together, they form the most complete picture available.
For background on what maitake is and how D-fraction is extracted from it, see what maitake mushroom is and why it's called the dancing mushroom.
Key Takeaways
- The only human clinical trial in breast cancer was the 2009 MSKCC phase I/II study: 34 disease-free survivors, immunological endpoints only, no tumor regression measured
- At intermediate doses, D-fraction produced non-monotonic immune effects: suppression at intermediate doses, enhancement at high doses. This finding is absent from most maitake coverage
- In laboratory studies, D-fraction activates the BAK-1 gene in breast cancer cells, triggering the self-destruction process that cancer cells normally evade (Soares et al., 2011)
- A 2013 genomic study found D-fraction alters expression of multiple genes controlling cell adhesion, migration, and invasion in breast cancer cell lines (Alonso et al., 2013)
- Triple-negative breast cancer cells treated with D-fraction showed decreased viability, less migration, and less invasive behavior in cell culture (Alonso et al., 2017)
- A non-randomized 165-patient case series reported 68.8% breast cancer response to MD-fraction; this is observational data without a control group (Kodama et al., 2002)
The MSKCC Trial: What 34 Disease-Free Survivors Were Actually Being Measured For
The 2009 Deng study is the most clinically credible piece of maitake breast cancer evidence, and it's worth being precise about what it tested, and what it didn't.[1]
The 34 women who participated were postmenopausal breast cancer survivors in complete remission. They were not in active treatment. The study did not test whether D-fraction could shrink tumors or prevent recurrence. What it measured was immune function: specifically whether oral D-fraction changed the activity of natural killer (NK) cells, T cells, and other immune markers in their blood.
This distinction is not a minor detail. A trial measuring immune effects in disease-free survivors is a different study than one testing treatment in people with active cancer. No randomized controlled trial of D-fraction in active breast cancer treatment exists.
The dose protocol tested was 0.1 to 5 milligrams of maitake D-fraction extract per kilogram of body weight, taken twice daily. Participants were tested at multiple doses using a crossover design, so each person served as their own control at different dose levels.
No dose-limiting toxicity was observed across the entire dose range. On safety, the MSKCC trial was reassuring.
The immunological results were considerably more complicated.
The Dose Paradox: When Intermediate Doses Suppress Instead of Boost
At intermediate doses, D-fraction suppressed immune function rather than enhancing it. At higher doses, it enhanced immune function. This non-monotonic dose-response pattern (where effects at the middle of a dose range run opposite to effects at the top) is documented in the Deng paper but rarely explained in writing about maitake.
This finding matters because people reading about maitake supplements often assume that taking more produces a stronger immune response. The MSKCC data shows that assumption doesn't hold at every dose point, at least for these immunological endpoints in these patients.
The mechanistic explanation for why this happens remains incompletely understood. Mushroom researchers have described maitake D-fraction as an immunomodulator rather than a simple immune enhancer. Its effects are context-dependent rather than uniformly stimulatory. This framing helps make sense of a pattern that would otherwise seem contradictory.
For a detailed explanation of the full immune cascade D-fraction triggers, including how it signals from macrophages to NK cells via interleukin-12, see how maitake D-fraction activates anti-tumor immunity. For the pharmacological foundation underlying these immune effects, see the pharmacology of Grifola frondosa.
What D-Fraction Does Inside a Breast Cancer Cell: The BAK-1 Mechanism
Moving from the clinical trial to the laboratory, the most specific mechanistic finding in breast cancer comes from Soares et al. in 2011.[2]
Soares' team treated breast cancer cell lines with D-fraction and measured what happened at the gene level. The central finding: D-fraction upregulated a gene called BAK-1.
BAK-1 is classified as a pro-apoptotic gene. Apoptosis is the process cells use to destroy themselves in a controlled way when they become damaged or abnormal: a kind of biological self-destruct sequence. In healthy tissue, apoptosis is a routine quality-control mechanism. Cancer cells often suppress the genes that trigger it, which is part of how they survive longer than they should. BAK-1 is one of the switches that initiates this self-destruction process.
When Soares' team applied D-fraction to the cancer cells, BAK-1 expression increased, and the cells began dying through apoptosis at higher rates. The extract also reduced angiogenesis, the formation of new blood vessels that tumors depend on to grow and sustain themselves. And it blocked the cells' ability to invade surrounding tissue.
Together, these three effects (more apoptosis, less blood vessel formation, less invasiveness) offer a mechanistic account of how D-fraction might slow tumor progression at the cell level.
These are findings from cultured cell lines, not from animal experiments or clinical trials. What happens in a laboratory dish doesn't always replicate in a living body. The BAK-1 data is compelling as a mechanistic hypothesis. It is not clinical evidence.
Beyond BAK-1: D-Fraction Rewrites Multiple Cancer-Associated Genes
Alonso et al. followed up in 2013 with a broader genomic analysis of what D-fraction does to breast cancer cells.[3]
Where Soares identified the BAK-1 pathway, the Alonso team looked at a wider panel of genes. They found that D-fraction altered the expression of multiple genes involved in cancer progression, specifically those controlling cell adhesion, cell migration, and cell invasion.
Each of these processes is a step in metastasis. A cancer cell that can't adhere to a new tissue can't establish a secondary tumor there. A cell that migrates poorly through the bloodstream is less likely to reach a distant organ. A cell that loses invasive capacity is less likely to penetrate surrounding healthy tissue.
The picture that emerges from the Alonso 2013 data is that D-fraction doesn't just push one button in breast cancer cells. It changes how those cells express a whole set of genes associated with aggressive cancer behavior. In practical terms: the treated cells started acting less like aggressive cancer and more like well-behaved tissue.
This is still cell-line data, with the same caveats as the Soares findings. But the breadth of the gene expression changes strengthens the BAK-1 finding, suggesting D-fraction's effects in breast cancer cells operate through multiple pathways, not a single switch.
Triple-Negative Breast Cancer: What the Cell Line Data Shows
Triple-negative breast cancer lacks the three most common hormone receptors: the estrogen receptor, the progesterone receptor, and HER2. This makes it the subtype most resistant to targeted therapies. It has a higher recurrence rate and more limited treatment options than other breast cancer subtypes.
Alonso et al. published a 2017 review that specifically addressed maitake D-fraction's effects on triple-negative cells, including the MDA-MB-231 cell line, a standard laboratory model for this aggressive subtype.[4]
The findings in triple-negative cells were consistent with what earlier studies found in other breast cancer cell lines: D-fraction decreased cell viability, increased cell adhesion, reduced migration, and reduced invasive behavior. The cells treated with D-fraction behaved less aggressively by every measure the researchers applied.
The phrase "less aggressive cell behavior" describes a real, quantified outcome in the laboratory. It doesn't directly translate into clinical benefit. What reduces aggressiveness in cells grown in a dish doesn't reliably predict what happens in a patient whose immune system, hormone environment, and tumor microenvironment are all factors.
The triple-negative data is the most clinically intriguing piece of breast cancer research in the D-fraction literature precisely because this subtype has the fewest targeted treatment options. But intriguing data from cell culture is a starting point for clinical research, not a conclusion from it.
For a cross-mushroom perspective on cancer research, including how maitake's evidence compares to reishi and turkey tail, see maitake D-fraction versus other mushroom cancer extracts. For context on how reishi compares in clinical cancer adjunct studies specifically, see Ganoderma lucidum as a cancer adjunct: clinical evidence.
The 68.8% Case Series: What That Number Actually Represents
The number that appears most often in maitake breast cancer content is 68.8%. It comes from a 165-patient case series published by Kodama et al. in 2002.[5]
Kodama's team collected reports from 165 Stage II through Stage IV cancer patients who took MD-fraction (a refined version of D-fraction with higher beta-glucan purity) at 100-150 mg per day alongside 4-6 grams of whole maitake powder. Some patients also received concurrent chemotherapy.
Among the breast cancer patients in that series, 68.8% showed either tumor regression or significant symptom improvement.
The liver cancer response rate was 58.3%. Lung cancer: 62.5%.
These are notable numbers. They're also from a case series: a structured collection of patient reports without a control group. There's no way to know how those same patients would have fared without MD-fraction. Many were receiving chemotherapy at the same time. The outcomes can't be cleanly separated from the other treatments.
Kodama's data is also where the finding that combining MD-fraction with chemotherapy improved response rates by 12-28% comes from. That's a meaningful-sounding number from a study design that can't establish causation.
None of this makes the case series useless. It's exactly how early signals get documented before researchers design controlled trials. The MSKCC phase I/II trial that followed was in part a response to data like Kodama's. But 68.8% is not the kind of number that can carry clinical conclusions on its own.
For more on the structural differences between D-fraction and MD-fraction, including why the case series used MD-fraction rather than the more common D-fraction, see maitake MD-fraction: the enhanced extract for cancer research.
Three Tiers of Evidence: Where Maitake D-Fraction Actually Stands
A 2020 review by Wong et al. structured the evidence for mushroom extracts in breast cancer across three tiers: cultured cancer cells, tumor-bearing animal models, and human clinical trials.[6] Maitake D-fraction has data across all three for breast cancer, which is more than most mushroom extracts can claim.
Tier 1: Cell culture: Multiple independent research groups have documented D-fraction's effects on breast cancer cells: BAK-1 activation, multi-gene expression changes, reduced invasiveness, and effects in triple-negative cell lines. The cell culture evidence is consistent and comes from separate teams working years apart. (Soares 2011, Alonso 2013, Alonso 2017)
Tier 2: Animal models: Exists in the broader D-fraction literature on tumor-bearing mice, though not specifically focused on breast cancer models in the studies surveyed for this article.
Tier 3: Human clinical trials: The MSKCC phase I/II trial (Deng 2009) with 34 disease-free breast cancer survivors. Immunological endpoints only. No tumor regression measured. No randomized controlled trial has tested D-fraction in active breast cancer treatment.
The gap between Tier 1 and Tier 3 is the honest story here. Compelling cell-line data showing apoptosis, gene suppression, and reduced aggressiveness in triple-negative cells has not been followed by a controlled clinical trial testing whether any of that translates to meaningful outcomes in patients with active breast cancer. That trial has not been done.
What the MSKCC study contributes is safety data across a wide dose range, immunological effects in a breast cancer survivor population, and the non-monotonic dose-response finding that complicates any simple narrative about "taking maitake boosts immunity."
For the complete picture of D-fraction evidence across all cancer types (not just breast), see maitake D-fraction and cancer: the complete research review. For broader context on how regular mushroom consumption relates to cancer risk at the population level, see daily mushroom consumption and cancer risk reduction.
The Bottom Line
Maitake D-fraction has three evidence streams in breast cancer research: laboratory studies documenting apoptosis and gene suppression in cell lines, including triple-negative models; a non-randomized 165-patient case series reporting a 68.8% response rate; and the 2009 Memorial Sloan Kettering phase I/II trial in 34 disease-free survivors that found immunological effects, not tumor regression. The MSKCC trial's most clinically important finding (that intermediate doses suppressed immune function) is underreported in most coverage of this topic. No randomized controlled trial has tested D-fraction in active breast cancer treatment.
Frequently Asked Questions
Sources & References
- 1. Source details for this reference are not yet available.
- 2. Source details for this reference are not yet available.
- 3. Source details for this reference are not yet available.
- 4. Source details for this reference are not yet available.
- 5RTHM-00095·Kodama, Noriko et al. (2002). “Can maitake MD-fraction aid cancer patients?.” Alternative medicine review : a journal of clinical therapeutic.Study breakdown →PubMed →↩
- 6. Source details for this reference are not yet available.